GKOS Glaukos Corp.: Enterprise Value to EBITDA Ratio

The complexity of treating glaucoma without invasive interventions is evident through the EV/EBITDA multiple trend, where the metric value stands at 0.00. Glaukos Corporation (GKOS) addresses this issue by developing miniature implants to preserve vision. High scientific potential is supported by investments in drug delivery systems, while the growth strategy relies on organic development and the deep integration of products into ophthalmological practice.

Glaukos Corp. - GKOS Company Value to EBITDA (period 11/23/2025 - 11/14/2026)

Analytical breakdowns and data insights for company glaukos.com (GKOS)

- current price and projected stock value:

Stock Price Glaukos Corp.|GKOS - Average Forecast Price

- company stock capitalization data:

Market Valuation Glaukos Medical|GKOS - Total Enterprise Value

- business book valuation details:

Book Value per Share Glaukos|GKOS - Total Stockholders' Equity|Market Value to Book Value Ratio glaukos.com|GKOS - Company Total Asset Base

- debt and liquidity data:

- financial results and valuation multiples details:

GKOS - Net Profit|Expected Profit Glaukos Corporation|GKOS - Market Cap to Earnings|Future Price to Earnings Glaukos Corporation|GKOS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Glaukos Medical|GKOS - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Glaukos|GKOS - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months glaukos.com|GKOS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Glaukos Corporation

- revenue and sales details:

GKOS - Company Sales Revenue|Company Projected Revenue Glaukos Corp.|GKOS - Price-to-Sales Ratio|Price-to-Projected Revenue Ratio Glaukos Medical

Summary company analytics:Glaukos Corp. GKOS

Investors assess the business's margin of safety through the ratio of enterprise value to EBITDA, determining the asset's value inclusive of debt. Amid the implementation of the iDose TR microimplant and the development of the R&D pipeline at Glaukos Corporation (GKOS), the EV/EBITDA multiple reflects the efficiency of innovation capitalization, allowing the asset to be classified as high-tech growth with a certain degree of valuation volatility risk.

Competitors of Glaukos Corporation

EV/EBITDA Multiple ALC (Alcon Vision)|Bausch Health (BLCO) - Company Value to EBITDA|APLS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Belite Bio Inc|OCUL: EV/EBITDA Multiple|Company Value to EBITDA Harrow Inc (HROW)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viridian Pharma|LENZ Corp (LENZ) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple OCS|eyepointpharma.com (EYPT) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kodiak Sciences KOD|Aldeyra Therapeutics Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kala Pharmaceuticals - EV/EBITDA Multiple|IRD - EV/EBITDA Multiple|OKYO (okyopharma.com) - Enterprise Value to EBITDA Ratio|Adverum Biotechnologies, Inc. (ADVM) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Outlook Therapeutics, Inc.|EV/EBITDA Multiple Clearside Biomedical Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NovaBay Pharmaceuticals (NBY)|KPRX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alimera Sciences, Inc. ALIM|Total Company Value to Operating Income Before Depreciation Ratio Eyenovia Inc. (EYEN)|GHSI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation OCUP (Ocuphire Pharma Inc)|OPT: EV/EBITDA Multiple